Are unreproducible results in cancer research harming patients?

The ability to reproduce results of published experiments helps prove affectability in future implementation. A major project in measuring the reliability of cancer research has found a lack of reproducibility to be damaging to the advancement of cancer treatments.

When cancer research is incapable of being reproduced by other researcher teams, the research is often left in the heap of unfinished projects. This heap is growing and growing while methods of cancer treatments remain stuck.

"Reproducibility is a central feature of how science is supposed to be," says Brian Nosek, a psychology professor at the University of Virginia.

An NPR article by Richard Harris explores reproducing cancer findings and what it means for the advancement of treatments. See the item below:

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.